Allogeneic Transplant After Brentuximab Vedotin in Patients with Relapsed/Refractory CD30+ Lymphomas


Allogeneic Transplant After Brentuximab Vedotin in Patients with Relapsed/Refractory CD30+ Lymphomas
Slides from a presentation at ASH 2011 and transcribed comments from a recent interview with Craig
Moskowitz, MD (1/11/12)

Illidge T et al. Allogeneic transplant following brentuximab vedotin treatment in patients with relapsed or refractory CD30+ lymphomas. Proc ASH 2011;Abstract 3091.

Dr Moskowitz is Clinical Director in the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center and Professor of Medicine at Weill Medical College of Cornell University in New York, New York.